Workflow
CEL-SCI (CVM)
icon
Search documents
CEL-SCI (CVM) - 2023 Q4 - Annual Report
2023-12-20 16:00
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under S ...
CEL-SCI (CVM) - 2023 Q3 - Quarterly Report
2023-08-09 16:00
Number Exhibit UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from _______________ to ______________. CEL-SCI CORPORATION Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant ...
CEL-SCI (CVM) - 2023 Q2 - Quarterly Report
2023-05-11 16:00
Summary of Significant Accounting Policies: Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash and cash equivalents. U.S. Treasury Bills – U.S. Treasury Bills ("T-bills") are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments ar ...
CEL-SCI (CVM) - 2023 Q1 - Quarterly Report
2023-02-13 16:00
New Accounting Pronouncements Impact of the COVID-19 Pandemic The following chart represents the warrants and non-employee options outstanding at December 31, 2022: In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss. During the three months ended December 31, 2022, 5,000 options with an exercise pric ...
CEL-SCI (CVM) - 2022 Q4 - Annual Report
2022-12-26 16:00
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________. Commission file number 1-11889 CEL-SCI CORPORATION (Exact name of registrant as specified in its charter) | --- | --- | |----------------------------- ...
CEL-SCI (CVM) - 2022 Q3 - Quarterly Report
2022-08-11 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to ______________. Commission File Number 001-11889 CEL-SCI CORPORATION Colorado State or other jurisdiction of incorporation | --- | |------ ...
CEL-SCI (CVM) - 2022 Q2 - Quarterly Report
2022-05-12 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Colorado 84-0916344 State or other jurisdiction incorporation (IRS) Employer Identification Number Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock CVM NYSE American Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated Filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF ...
CEL-SCI (CVM) - 2022 Q1 - Quarterly Report
2022-02-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to ______________. Commission File Number 001-11889 | --- | --- | --- | |----------------------------------------------|----------------- ...
CEL-SCI (CVM) - 2021 Q4 - Annual Report
2021-12-20 16:00
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________. Commission file number 1-11889 CEL-SCI CORPORATION (Exact name of registrant as specified in its charter) | --- | --- | |----------------------------- ...
CEL-SCI (CVM) - 2021 Q3 - Quarterly Report
2021-08-12 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock CVM NYSE American Large accelerated filer ☐ Accelerated filer Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Class of Stock No. Shares Outstanding Date Common 43,028,150 August 9, 2021 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly p ...